BEDFORD, Mass., March 15, 2018 – Homology Medicines, Inc., a genetic medicines company, announced today the appointment of Mary Thistle, Chief of Staff of the Bill & Melinda Gates Medical Research Institute, to Homology’s Board of Directors. Ms. Thistle has more than 25 years of experience in finance, strategy and business development functions across different therapeutic areas, including gene therapy.
“Mary has extensive strategic operations, business development and finance experience that we can leverage to advance our nuclease-free gene editing and gene therapy platform,” said Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. “We believe the recent addition of two independent and experienced members to our Board strengthens our ability to deliver on our mission to cure patients with genetic diseases.”
Prior to joining the Bill & Melinda Gates Medical Research Institute, Ms. Thistle was Chief Operating Officer of Dimension Therapeutics Inc. At Dimension, she oversaw the company’s Series B financing and initial public offering, expanded the pipeline through strategic business development transactions, and led the sale of the company to Ultragenyx Pharmaceutical Inc. Prior, Ms. Thistle was the Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for multiple acquisitions and assisted in the sale to Merck. Ms. Thistle held senior level positions at ViaCell Inc. in finance, operations and business development, and then served as Senior Vice President, Business Development at Perkin Elmer after ViaCell was acquired. Ms. Thistle began her career in finance as a Certified Public Accountant. Ms. Thistle also serves on the Board of Directors of Enterome SA and is a graduate of the Women in Bio Boardroom Ready program.
“Homology is pursuing scientific and business strategies to advance the Company’s gene therapy and gene editing platform toward the clinic,” said Ms. Thistle. “Patients with rare diseases need more options that have the potential to address the underlying genetic cause of disease, and I am excited to join the Board and work with the Homology team with the goal of bringing new treatments forward.”
About Homology Medicines, Inc.
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.